A randomized phase I clinical and biologic study of two schedules of the raf-kinase inhibitor BAY 43-9006 in patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML): A NCI Canada clinical trials group study Conference Paper uri icon

  •  
  • Overview
  •  
  • Research
  •  
  • Additional Document Info
  •  
  • View All
  •  

authors

  • Crump, M
  • Leber, Brian
  • Buckstein, R
  • Kassis, J
  • Matthews, JH
  • Robinson, S
  • Turner, R
  • Hedley, D
  • Petrenciuc, O
  • McIntosh, L
  • Seymour, L

publication date

  • November 16, 2002

published in